Corvus Pharmaceuticals CRVS Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's financing cash flow?
- Corvus Pharmaceuticals (CRVS) reported financing cash flow of $190.75M in Q1 2026.
- How has Corvus Pharmaceuticals's financing cash flow changed year-over-year?
- Corvus Pharmaceuticals's financing cash flow increased by 68267.7% year-over-year, from $279K to $190.75M.
- What is the long-term trend for Corvus Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Corvus Pharmaceuticals's financing cash flow has grown at a -16.3% compound annual growth rate (CAGR), from $62.16M to $36.43M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.